文献速递炎症性肠病消化道肿瘤与早癌

系统综述与荟萃分析:免疫检查点抑制剂在既往炎症性肠病患者中的安全性与耐受性

Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2020-12-12

该系统综述与荟萃分析纳入12项研究、193例既往炎症性肠病患者,评估免疫检查点抑制剂治疗后的不良结局。荟萃分析显示40%患者出现炎症性肠病复发,复发者中76%需糖皮质激素、37%需生物制剂,35%患者停用免疫检查点抑制剂;CTLA-4抑制剂可能与更高复发风险相关。

要点

  • 既往炎症性肠病患者使用免疫检查点抑制剂后约40%出现复发。
  • 复发者中76%需糖皮质激素,37%需生物制剂治疗。
  • 约35%患者因不良结局停用免疫检查点抑制剂。

核心结论

  • 约40%既往炎症性肠病患者使用免疫检查点抑制剂后出现复发,多数复发者需糖皮质激素、约三分之一需生物制剂。
  • CTLA-4抑制剂可能与更高的复发风险相关。

研究设计与样本

  • 系统文献综述截至2020年7月31日,纳入12项研究、193例既往炎症性肠病患者。
  • 采用随机效应荟萃分析计算合并率(95%CI),并对个体研究进行定性综合评估不良结局相关危险因素。

主要发现

  • 荟萃分析显示40%患者(95%CI 26%-55%)使用免疫检查点抑制剂后出现炎症性肠病复发。
  • 复发患者中76%(95%CI 65%-85%)需糖皮质激素,37%(95%CI 22%-53%)需生物制剂。
  • 35%患者(95%CI 17%-57%)停用免疫检查点抑制剂。
  • 免疫检查点抑制剂并发症导致的胃肠穿孔和腹部手术发生于<5%患者。
  • 一项大型研究中,CTLA-4抑制剂较PD-1和PD-L1抑制剂与更高的复发风险相关。

临床怎么用

  • 对既往炎症性肠病患者使用免疫检查点抑制剂前应评估复发风险并监测炎症性肠病活动。
  • 复发时多数患者需糖皮质激素,约三分之一需生物制剂,应提前规划管理策略。
  • 选择免疫检查点抑制剂类型时需考虑CTLA-4抑制剂可能更高的复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors may variably impact patients with pre-existing autoimmune diseases. AIMS: To evaluate the risks and outcomes of adverse events in patients with pre-existing inflammatory bowel diseases treated with immune checkpoint inhibitors. METHODS: Through a systematic literature review up until July 31, 2020, we identified 12 studies reporting the impact of immune checkpoint inhibitors in 193 patients with inflammatory bowel disease. Outcomes of interest were relapse of inflammatory bowel disease, need for corticosteroids and/or biologics to manage inflammatory bowel disease relapse, and discontinuation of immune checkpoint inhibitors. We calculated pooled rates (with 95% confidence intervals [CI]) using random effects meta-analysis, and examined risk factors associated with adverse outcomes through qualitative synthesis of individual studies. RESULTS: On meta-analysis, 40% patients (95% CI, 26%-55%) experienced relapse of inflammatory bowel disease with immune checkpoint inhibitors. Among patients who experienced relapse, 76% (95% CI, 65%-85%) required corticosteroids, and 37% (95% CI, 22%-53%) required biologic therapy. Overall, 35% patients (95% CI, 17%-57%) with inflammatory bowel disease discontinued immune checkpoint inhibitors. Gastrointestinal perforation and abdominal surgery due to immune checkpoint inhibitor complications occurred in <5% patients. In a large study, inhibitors of cytotoxic T-lymphocyte antigen-4 (CTLA-4) were associated with a higher risk of relapse than programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors. CONCLUSIONS: Approximately 40% of patients with pre-existing inflammatory bowel diseases experience relapse with immune checkpoint inhibitors, with most relapsing patients requiring corticosteroids and one-third requiring biologics. CTLA-4 inhibitors may be associated with higher risk of relapse.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Meserve J, Facciorusso A, Holmer AK, et al. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2020. PMID: 33314269. doi:10.1111/apt.16217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。